The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | The future of CAR-T and bispecifics in myeloma: successful integration into earlier lines
Borja Puertas, MD, University Hospital of Salamanca, Salamanca, Spain, discusses the future of CAR T-cell therapy and bispecific antibodies for treating multiple myeloma (MM), emphasizing the necessity to incorporate them into earlier treatment lines due to an increasing number of patients becoming triple-class exposed or refractory after minimal prior treatment. Dr Puertas highlights CAR T-cell therapy as a potential standard of care for high-risk patients, with emerging evidence supporting its use as first-line consolidation therapy for patients with suboptimal responses. Similarly, bispecifics may prove effective at first relapse in those with aggressive disease or as maintenance/consolidation in early lines. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
